Hyperium (Rilmenidine Dihydrogen Phosphate)

Rilmenidine works by selectively stimulating imidazoline I1 receptors in the brainstem, particularly the rostral ventrolateral medulla. This activation suppresses sympathetic outflow, leading to reduced norepinephrine release, lower peripheral vascular resistance, and consequently a decrease in arterial blood pressure. The focused receptor action provides antihypertensive effects with limited impact on other adrenergic pathways.

The appropriate dose of Hyperium is determined individually by a prescriber based on the patient’s blood pressure, age, renal function, and overall clinical condition. Physicians may start with a low dose and adjust as needed to reach target blood pressure while monitoring for tolerability. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of Hyperium in pregnancy and lactation has not been definitively established; its pregnancy category is listed as unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Hyperium, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Hyperium (rilmenidine) belongs to the imidazoline receptor agonist class, which differs from more common agents such as ACE inhibitors, beta‑blockers, or calcium‑channel blockers. It primarily reduces central sympathetic outflow, whereas other classes act on the renin‑angiotensin system, heart rate, or vascular smooth muscle. Clinical choice depends on patient profile, tolerability, and any comorbid conditions.

Hyperium tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in a refrigerator or freezer, and avoid exposure to excessive heat or humidity.

Hyperium is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing. Swallow the tablet whole; do not crush, chew, or split it unless specifically advised by a healthcare professional.

The most serious adverse events associated with Hyperium include severe hypotension leading to fainting, syncope, hepatic dysfunction indicated by abnormal liver enzymes, allergic reactions that may progress to anaphylaxis, neutropenia which can increase infection risk, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any of these symptoms.

Hyperium should be avoided in individuals with known hypersensitivity to rilmenidine or any excipients in the tablet, patients with severe hypotension, or those with uncontrolled heart failure. Caution is also advised for patients with significant renal impairment, the elderly, and anyone taking interacting central antihypertensives without medical supervision.